XML 66 R56.htm IDEA: XBRL DOCUMENT
v3.23.3

Investment in Cyclo Therapeutics, Inc. (Details) - USD ($) $ / shares in Units, $ in Thousands |  |  |  | 1 Months Ended | 2 Months Ended | 3 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Oct. 31, 2023 | Oct. 20, 2023 | Jun. 01, 2023 | Jul. 31, 2023 | Oct. 31, 2023 | Oct. 31, 2023 | Aug. 01, 2023 | Apr. 30, 2023 | Feb. 09, 2023 | Nov. 15, 2021
Investment in Cyclo Therapeutics Inc Details [Line Items] |  |  |  |  |  |  |  |  |  |
Purchase agreement, description |  |  |  |  |  | The Company purchased from Cyclo (i) 2,514,970 common shares (the “Purchased Shares”) and (ii) a warrant to purchase 2,514,970 common shares with an exercise price of $0.71 per share (the “May Warrant”), at a combined purchase price equal to $0.835 per Purchased Share and May Warrant to purchase one share, for an aggregate purchase price of $2.1 million. |  |  |  |
Additional common shares (in Shares) |  | 2,766,467 | 4,000,000 |  |  |  |  |  |  |
Warrant purchase shares (in Shares) |  |  | 4,000,000 |  |  |  |  |  |  |
Aggregate purchase amount |  |  | $ 5,000,000 |  |  |  |  |  |  |
Common shares (in Shares) |  | 2,514,970 |  |  |  |  |  |  |  |
Exercise price (in Dollars per share) |  |  |  | $ 1.75 |  |  |  | $ 1.75 |  |
Exercise price (in Dollars per share) |  |  |  |  |  |  |  |  | $ 0.03 |
Common stock, percentage |  | 40.00% |  |  |  |  |  |  |  |
Unrealized loss |  |  |  |  |  | $ 2,100 |  |  |  |
Total aggregate fair value | $ 9,849,042 |  |  | $ 4,763,102 |  |  |  |  |  |
Warrant [Member] |  |  |  |  |  |  |  |  |  |
Investment in Cyclo Therapeutics Inc Details [Line Items] |  |  |  |  |  |  |  |  |  |
Exercise price (in Dollars per share) |  |  |  |  |  |  |  |  | $ 0.03 | $ 0.1878
Realized gain |  |  |  |  | $ 424 |  |  |  |  |
Investment in Cyclo Therapeutics, Inc. [Member] |  |  |  |  |  |  |  |  |  |
Investment in Cyclo Therapeutics Inc Details [Line Items] |  |  |  |  |  |  |  |  |  |
Exercise price (in Dollars per share) |  |  | $ 1.25 |  |  |  |  |  |  |
Ownership percentage | 40.00% |  |  |  | 40.00% | 40.00% | 34.00% |  |  |
Exercise price (in Dollars per share) |  | $ 0.71 |  |  |  |  |  |  |  |
Exercise price (in Dollars per share) |  | $ 0.95 |  |  |  |  |  |  |  |
Aggregate fair value | $ 8,759,042 |  |  | 3,898,204 | $ 8,759,042 | $ 8,759,042 |  |  |  |
Investment in Cyclo Therapeutics, Inc. [Member] | Warrant [Member] |  |  |  |  |  |  |  |  |  |
Investment in Cyclo Therapeutics Inc Details [Line Items] |  |  |  |  |  |  |  |  |  |
Ownership percentage | 49.00% |  |  |  | 49.00% | 49.00% |  |  |  |
Aggregate fair value | $ 1,090,000 |  |  | $ 864,898 | $ 1,090,000 | $ 1,090,000 |  |  |  |

X
- Definition Additional shares. + References No definition available. + Details
Name: | rfl_AdditionalShares
Namespace Prefix: | rfl_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate purchase amount. + References No definition available. + Details
Name: | rfl_AggregatePurchaseAmount
Namespace Prefix: | rfl_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Common shares. + References No definition available. + Details
Name: | rfl_CommonShares
Namespace Prefix: | rfl_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | rfl_InvestmentInCycloTherapeuticsIncDetailsLineItems
Namespace Prefix: | rfl_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Purchase agreement, description. + References No definition available. + Details
Name: | rfl_PurchaseAgreementDescription
Namespace Prefix: | rfl_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total aggregate fair value. + References No definition available. + Details
Name: | rfl_TotalAggregateFairValue
Namespace Prefix: | rfl_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Warrant purchase shares. + References No definition available. + Details
Name: | rfl_WarrantPurchaseShares
Namespace Prefix: | rfl_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate fair value of additional assets that would be required to be posted as collateral for derivative instruments with credit-risk-related contingent features if the credit-risk-related contingent features were triggered at the end of the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4H -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4H + Details
Name: | us-gaap_AdditionalCollateralAggregateFairValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of unrealized gain (loss) on investment in debt and equity securities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column D)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column D)(Footnote 6)(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column D)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1 + Details
Name: | us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1 + Details
Name: | us-gaap_DebtSecuritiesRealizedGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Purchase price of common stock expressed as a percentage of its fair value. + References No definition available. + Details
Name: | us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rfl_InvestmentInCycloTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |